These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9403091)

  • 1. [Multiple sclerosis: from immunopathogenesis to disease management].
    Nervenarzt; 1996 Dec; 67(12 Suppl Von Der Im):1-8. PubMed ID: 9403091
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.
    Weiner HL
    Arch Neurol; 2004 Oct; 61(10):1613-5. PubMed ID: 15477521
    [No Abstract]   [Full Text] [Related]  

  • 3. Copolymer 1 from the laboratory to FDA.
    Teitelbaum D; Sela M; Arnon R
    Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880
    [No Abstract]   [Full Text] [Related]  

  • 4. [Multiple sclerosis].
    Offenhäusser M; Martin R
    Med Monatsschr Pharm; 1997 Jun; 20(6):149-57. PubMed ID: 9289627
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunopathogenesis of multiple sclerosis: implications for treatment.
    Waldron-Lynch F; Hennessy MJ
    Ir Med J; 2004 Jan; 97(1):5-6. PubMed ID: 15055909
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunosuppressive treatment of multiple sclerosis (review of the literature].
    Neretin VIa; Kir'iakov VA; Sapfirova VA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(2):119-26. PubMed ID: 2160156
    [No Abstract]   [Full Text] [Related]  

  • 7. [Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy].
    MMW Fortschr Med; 2008 Apr; 150(15):17. PubMed ID: 18510111
    [No Abstract]   [Full Text] [Related]  

  • 8. [Various aspects of immunopathogenesis of multiple sclerosis and therapeutic possibilities].
    Aleksandrowicz J; Blicharski J; Skotnicki A; Retinger M; Zduńczyk A
    Pol Tyg Lek; 1981 Aug; 36(35):1363-5. PubMed ID: 7036112
    [No Abstract]   [Full Text] [Related]  

  • 9. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F; Kieseier BC
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current data on the etiopathogenesis of multiple sclerosis].
    Duca E
    Neurol Psihiatr Neurochir; 1972; 17(5):385-94. PubMed ID: 4632587
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of multiple sclerosis and other autoimmune diseases with cladribine.
    Beutler E; Sipe J; Romine J; McMillan R; Zyroff J; Koziol J
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):45-52. PubMed ID: 8714617
    [No Abstract]   [Full Text] [Related]  

  • 12. [Glatiramer for relapsing-remitting multiple sclerosis].
    Hennemann A
    Med Monatsschr Pharm; 2002 Apr; 25(4):141-2. PubMed ID: 12017128
    [No Abstract]   [Full Text] [Related]  

  • 13. Glatiramer acetate in the treatment of multiple sclerosis.
    Miller AE
    Neurol Clin; 2005 Feb; 23(1):215-31, viii. PubMed ID: 15661095
    [No Abstract]   [Full Text] [Related]  

  • 14. Solving the MS puzzle.
    Hobson K
    US News World Rep; 2002 Oct; 133(13):60-2. PubMed ID: 12375480
    [No Abstract]   [Full Text] [Related]  

  • 15. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostics and drug therapy of multiple sclerosis].
    Suomen Neurologinen Yhdistys ry
    Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunosuppressive therapy].
    Schumacher K; Gross R
    Internist (Berl); 1984 Jan; 25(1):51-9. PubMed ID: 6370894
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interaction of central nervous system local immunity and systemic immunity during multiple sclerosis].
    Tourtellotte WW
    Rev Neurol (Paris); 1972 Nov; 127(5):497-504. PubMed ID: 4588993
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacologic constraints imposed by the blood-brain barrier: the example of multiple sclerosis].
    Jolliet P
    Rev Neurol (Paris); 2000 Jul; 156(6-7):681-3. PubMed ID: 10891808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.